COVID-19 Human IgA ELISA kit (Spike Protein)(Full-Length)
Measurement method : Indirect ELISA
Measurement wavelength : 450 nm
Measurement sample : Serum, saliva, sputum
Species reactivity : Human
Storage temperature : Store at 2-8° C.
Expiration date : 6 months after production
Immobilized antigen : SARS-CoV-2 Spike protein (S1 + S2 domain, mammalian expression system)
1. SARS-CoV-2 spike protein-immobilized plate
2. HRP-conjugated anti-human IgA antibody
3. Washing buffer（10× PBST）
4. Non-fat milk (for blocking buffer)
5. Diluent buffer (10×)
6. R-1: Chromogenic substrate (TMB)
7. R-2: Stop reagent (1 mol/L hydrochloric acid)
8. Microplate seal
The SARS-CoV-2 recombinant spike protein immobilized on the plate is recognized and reacted with the antibody (hereinafter, abbreviated as anti-spike protein antibody) in a sample
After the reaction, the sample is removed by washing.
The anti-spike protein antibody is reacted with HRP (Horseradish peroxidase)-conjugated anti-human IgA antibody.
Remove excess HRP-conjugated anti-human IgA antibody by washing. Add a chromogenic substrate and measure the absorbance.
Significance of measurement
This kit is a research ELISA kit to detect human IgA antibody that recognizes the spike protein of SARS-CoV-2, the causative virus of Covid-19.
Virus detection can be broadly divided into two approaches: one is to detect the virus itself, such as PCR method, and the other is to detect the immune response that develops during infection (IgG, IgM, IgA). IgA is particularly abundant in mucous membranes such as saliva and the nasopharynx, and generally has the function of infection prevention.
Clin Chim Acta. 2020 Sep 28. PubMed PMID: 33002475
Massimo Guerriero et al.
Prevalence of asymptomatic SARS-CoV-2-positive individuals in the general population of northern Italy and evaluation of a diagnostic serological ELISA test: a cross-sectional study protocol
BMJ Open. 2020 Oct 6. PubMed PMID: 33028562
Ekasit Kowitdamrong et al.
Antibody responses to SARS-CoV-2 in patients with differing severities of coronavirus disease 2019
PLoS One. 2020 Oct 9. PubMed PMID: 33035234
Immunol Invest. 2020 Sep 18. PubMed PMID: 32945214
Suzanne Pickering et al.
Comparative assessment of multiple COVID-19 serological technologies supports continued evaluation of point-of-care lateral flow assays in hospital and community healthcare settings
PLoS Pathog . 2020 Sep 24. PubMed PMID: 32970782
Christian Wechselberger et al.
Performance evaluation of serological assays to determine the immunoglobulin status in SARS-CoV-2 infected patients
J Clin Virol. 2020 Oct. PubMed PMID: 32810840
Zahra Rikhtegaran Tehrani et al.
Specificity and Performance of Nucleocapsid and Spike-based SARS-CoV-2 Serologic Assays
medRxiv. 2020 Aug 7. PubMed PMID: 32793933
Fatima Amanat et al.
Nat Med. 2020 Jul. PubMed PMID: 32398876
Jonathan J Deeks et al.
Antibody tests for identification of current and past infection with SARS-CoV-2
Cochrane Database Syst Rev. 2020 Jun 25. PubMed PMID: 32584464
Sci Immunol. 2020 Jun 11. PubMed PMID: 32527802
Nadin Younes et al.
Challenges in Laboratory Diagnosis of the Novel Coronavirus SARS-CoV-2
Viruses. 2020 May 26. PubMed PMID: 32466458
1.)Keiichi Hiramatsu, Standard Textbook of standard microbiology, 11th edition, Medical study (2012)
2.)Andrea Padoan, IgA-Ab response to spike glycoprotein of SARS-CoV-2 in patients with COVID-19: A longitudinal study, Clinica Chimica Acta, 507, 164-166, Aug., 2020
5.)Yin Xia Chao, The role of IgA in COVID-19, Brain, Behavior, and Immunity, 87, Jul., 2020